 |
Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP) |
|---|---|
| Trade Name | |
| Orphan Indication | Graft Versus Host Disease |
| USA Market Approval | USA |
| USA Designation Date | 1999-11-24 00:00:00 |
| Sponsor | Bellicum Pharmaceuticals, Inc.;6400 Fannin Street, Suite 2300;Houston, Texas, 77030 |
